Skip to content

Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00731809
Enrollment
50
Registered
2008-08-11
Start date
2008-04-30
Completion date
2010-10-31
Last updated
2008-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Keywords

Crohn's disease

Brief summary

18F-FDG PET/CT (2-\[fluorine-18\] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body. 18F-FDG uptake is caused by increased local metabolic activity. Such increased uptake has been described not only in neoplastic lesions but also in inflammatory lesions. In this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the bowel, especially the cecum, and has limited the use of PET in inflammatory bowel diseases. The advantage of combined PET and CT devices lead to significant improvements in the interpretation of the bowel areas, and greatly reduces the number of false-positive findings in the gastrointestinal tract.

Interventions

RADIATIONFDG PET CT

FDG PET CT

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients suspicious for active disease: * Patients with suspected but undiagnosed Crohn's disease * Patients with serological markers of inflammation (elevated ESR, CRP or thrombocytosis) but clinically in remission * Patients with a stricture which might be fibrous in which case surgery is indicated or inflammatory for which medical management is indicated * Able to sign a consent form

Exclusion criteria

* Pregnancy * Breastfeeding * Infectious colitis determined at the initial checkup * Allergy to iodine contrast

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026